{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:02:53Z","timestamp":1785934973930,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pharmacovigilance aims at a better understanding of the molecular events triggered by medications to prevent adverse effects, which despite significant advances in our analytical repertoire plague the use of drugs until today. In this study, we find that clinically prescribed and commercially available pirenzepine may not be the correct compound. Pirenzepine can undergo an unexpected scaffold rearrangement from the pharmaceutical active ingredient (API) to a previously uncharacterized benzimidazole. The rearrangement occurs under highly acidic conditions, which were believed to favour the dihydrochloride formation of pirenzepine. The rearranged products of pirenzepine and the structurally related telenzepine have significantly decreased affinity for the muscarinic acetylcholine receptor, the pharmacological target of these compounds. Fortunately, in situ rearrangement after oral application is no safety issue, as we show that reaction kinetics in gastric acid prevent rearrangement. The research community should consider appropriate measures to perform reliable receiving inspections in the commercial supply of well described and frequently used chemicals, in particular if experiments yield unexpected results.<\/jats:p>","DOI":"10.1038\/s41598-021-02732-y","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T11:03:41Z","timestamp":1638529421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Unexpected scaffold rearrangement product of pirenzepine found in commercial samples"],"prefix":"10.1038","volume":"11","author":[{"given":"Marius","family":"Ozenil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Skos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Roller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Spreitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Platzer-Ozenil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Vraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wadsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"2732_CR1","unstructured":"Lang, N. et al. How the global chemical industry has become a battle of equals. https:\/\/www.bcg.com\/publications\/2015\/globalization-automotive-how-global-chemical-industry-become-battle-equals.aspx (2015)."},{"key":"2732_CR2","unstructured":"Jung, U., Rothman, A., Mahnke, T. & Roth, R. Why speciality chemical distributors need to raise their game. https:\/\/www.bcg.com\/de-at\/publications\/2018\/why-specialty-chemical-distributors-need-to-raise-their-game.aspx (2018)."},{"key":"2732_CR3","unstructured":"Heavey, S. & Richwine, L. U.S., China clash over heparin contaminant\u2019s role. Reuters https:\/\/www.reuters.com\/article\/us-heparin-china-idUSN2142999820080422 (2008)."},{"key":"2732_CR4","unstructured":"Bogdanich, W. & Hooker, J. From China to Panama, a trail of poisoned medicine. The New York Times. https:\/\/www.nytimes.com\/2007\/05\/06\/world\/americas\/06poison.html (2007)."},{"key":"2732_CR5","first-page":"684","volume":"27","author":"H Brunner","year":"1977","unstructured":"Brunner, H., Veri\u00e1, M., Polterauer, P. & Grabner, G. Effect of pirenzepine, a new gastric acid-inhibiting agent, on exocrine pancreatic secretion in man. Arzneimittelforschung 27, 684\u2013687 (1977).","journal-title":"Arzneimittelforschung"},{"key":"2732_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003495-198530020-00001","volume":"30","author":"AA Carmine","year":"1985","unstructured":"Carmine, A. A. & Brogden, R. N. Pirenzepine. Drugs 30, 85\u2013126 (1985).","journal-title":"Drugs"},{"key":"2732_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/cxo.12666","volume":"101","author":"P Kang","year":"2018","unstructured":"Kang, P. Optical and pharmacological strategies of myopia control: Myopia control. Clin. Exp. Optom. 101, 321\u2013332 (2018).","journal-title":"Clin. Exp. Optom."},{"key":"2732_CR8","unstructured":"A 24-week study of topical pirenzepine or placebo in type 2 diabetic patients (T2DM) with peripheral neuropathy. U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04005287 (2019)."},{"key":"2732_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/283090a0","volume":"283","author":"R Hammer","year":"1980","unstructured":"Hammer, R., Berrie, C. P., Birdsall, N. J. M., Burgen, A. S. V. & Hulme, E. C. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283, 90\u201392 (1980).","journal-title":"Nature"},{"key":"2732_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mds.870010208","volume":"1","author":"RE Burke","year":"1986","unstructured":"Burke, R. E. The relative selectivity of anticholinergic drugs for the M1 and M2 muscarinic receptor subtypes. Mov. Disord. 1, 135\u2013144 (1986).","journal-title":"Mov. Disord."},{"key":"2732_CR11","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1096\/fj.201902113R","volume":"34","author":"V Cilleros-Ma\u00f1\u00e9","year":"2020","unstructured":"Cilleros-Ma\u00f1\u00e9, V. et al. The M 2 muscarinic receptor, in association to M 1, regulates the neuromuscular PKA molecular dynamics. FASEB J. 34, 4934\u20134955 (2020).","journal-title":"FASEB J."},{"key":"2732_CR12","unstructured":"Pirenzepine. Drugs.com. https:\/\/www.drugs.com\/international\/pirenzepine.html."},{"key":"2732_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0099-5428(08)60563-8","volume":"16","author":"HA El-Obeild","year":"1987","unstructured":"El-Obeild, H. A., Babhair, S. A. & Al-Badr, A. A. Pirenzepine dihydrochloride. Anal Profiles Subst 16, 445\u2013506 (1987).","journal-title":"Anal Profiles Subst"},{"key":"2732_CR14","unstructured":"Pirenzepine. https:\/\/www.drugbank.ca\/drugs\/DB00670."},{"key":"2732_CR15","unstructured":"Schmidt, G. D.-C. D., Engelhorn, R. D. & Leitold, M. D. 11-Substituted 5 11-dihydro-6h-pyrido(2 3-B)(1 4)benzodiazepin-6-ones (1972)."},{"key":"2732_CR16","unstructured":"Eberlein, W. D. C. D. & Breuer, G. Process for the preparation of 5,11-dihydro-11-((4-methyl-1-piperazinyl)-acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one (1984)."},{"key":"2732_CR17","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1135\/cccc19881820","volume":"53","author":"H Hulinsk\u00e1","year":"1988","unstructured":"Hulinsk\u00e1, H. et al. Experimental antiulcer agents: N-substituted 2-(4-methyl-1-piperazinyl)acetamides as pirenzepine models and some related compounds. Collect. Czechoslov. Chem. Commun. 53, 1820\u20131844 (1988).","journal-title":"Collect. Czechoslov. Chem. Commun."},{"key":"2732_CR18","unstructured":"Zhang, Y. Pirenzepine production method. Patent number CN104744457 (A) (2015)."},{"key":"2732_CR19","unstructured":"Yang, Y. Method for synthesizing pirenzepine hydrochloride. Patent number CN103044419 (A) (2013)."},{"key":"2732_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/jhet.5570200537","volume":"20","author":"T Kova\u010d","year":"1983","unstructured":"Kova\u010d, T. et al. New synthesis of 11-acyl-5,11-dihydro-6 H -pyrido[2,3-b][1,4]-benzodiazepin-6-ones and related studies: New Synthesis of 11-Acyl-5,11-dihydro-6 H -pyrido[2,3-b][1,4]-benzodiazepin-6-ones. J. Heterocycl. Chem. 20, 1339\u20131349 (1983).","journal-title":"J. Heterocycl. Chem."},{"key":"2732_CR21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/jhet.5570260505","volume":"26","author":"M Bud\u011b\u0161\u00ednsk\u00fd","year":"1989","unstructured":"Bud\u011b\u0161\u00ednsk\u00fd, M. et al. Unexpected formation of a 11 H -pyrido[2,1- b ]quinazolin-11-one derivative from 5,11-dihydro-6 H -pyrido[2,3- b ]-1,4-benzodiazepin-6-one. J. Heterocycl. Chem. 26, 1229\u20131235 (1989).","journal-title":"J. Heterocycl. Chem."},{"key":"2732_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.scitotenv.2013.06.027","volume":"466\u2013467","author":"SM Mitchell","year":"2014","unstructured":"Mitchell, S. M., Ullman, J. L., Teel, A. L. & Watts, R. J. pH and temperature effects on the hydrolysis of three \u03b2-lactam antibiotics: Ampicillin, cefalotin and cefoxitin. Sci. Total Environ. 466\u2013467, 547\u2013555 (2014).","journal-title":"Sci. Total Environ."},{"key":"2732_CR23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s10593-017-2156-z","volume":"53","author":"T Dra\u017ei\u0107","year":"2017","unstructured":"Dra\u017ei\u0107, T. & Roje, M. \u03b2-Lactam rearrangements into five-membered heterocycles. Chem. Heterocycl. Compd. 53, 953\u2013962 (2017).","journal-title":"Chem. Heterocycl. Compd."},{"key":"2732_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000138507","volume":"37","author":"RW Stockbr\u00fcgger","year":"1988","unstructured":"Stockbr\u00fcgger, R. W. Clinical significance of M1 receptor antagonists. Pharmacology 37, 54\u201363 (1988).","journal-title":"Pharmacology"},{"key":"2732_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1124\/mol.53.2.304","volume":"53","author":"C Tr\u00e4nkle","year":"1998","unstructured":"Tr\u00e4nkle, C., Andresen, I., Lambrecht, G. & Mohr, K. M2 Receptor binding of the selective antagonist AF-DX 384: Possible involvement of the common allosteric site. Mol. Pharmacol. 53, 304\u2013312 (1998).","journal-title":"Mol. Pharmacol."},{"key":"2732_CR26","first-page":"628","volume":"241","author":"R Micheletti","year":"1987","unstructured":"Micheletti, R., Montagna, E. & Giachetti, A. AF-DX 116, a cardioselective muscarinic antagonist. J. Pharmacol. Exp. Ther. 241, 628\u2013634 (1987).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2732_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0014-2999(91)90081-Z","volume":"192","author":"H Doods","year":"1991","unstructured":"Doods, H., Entzeroth, M. & Mayer, N. Cardioselectivity of AQ-RA 741, a novel tricyclic antimuscarinic drug. Eur. J. Pharmacol. 192, 147\u2013152 (1991).","journal-title":"Eur. J. Pharmacol."},{"key":"2732_CR28","doi-asserted-by":"publisher","first-page":"112623","DOI":"10.1016\/j.ejmech.2020.112623","volume":"204","author":"M Ozenil","year":"2020","unstructured":"Ozenil, M. et al. Enhanced arecoline derivatives as muscarinic acetylcholine receptor M1 ligands for potential application as PET radiotracers. Eur. J. Med. Chem. 204, 112623 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"2732_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1071\/CH9661013","volume":"19","author":"P Bolton","year":"1966","unstructured":"Bolton, P. Hydrolysis of amides. II. Substituent effects in dilute acid and alkali. Aust. J. Chem. 19, 1013 (1966).","journal-title":"Aust. J. Chem."},{"key":"2732_CR30","unstructured":"\u76d0\u9178\u54cc\u4ed1\u897f\u5e73\u7247. https:\/\/www.larspring.com\/front\/product\/toProduct?uuid=551ae1c9ea1d4f70b116c4561ccd2d16."},{"key":"2732_CR31","unstructured":"\u76d0\u9178\u54cc\u4ed1\u897f\u5e73\u7247. https:\/\/www.yaofangwang.com\/medicine-318468.html."},{"key":"2732_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0378-4347(00)83132-1","volume":"430","author":"E Sturm","year":"1988","unstructured":"Sturm, E. & Junker, A. Determination of telenzepine in human serum by gas chromatography: Mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 430, 43\u201351 (1988).","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"2732_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3389\/fchem.2019.00568","volume":"7","author":"C Ostacolo","year":"2019","unstructured":"Ostacolo, C. et al. An efficient approach to aromatic aminomethylation using dichloromethane as methylene source. Front. Chem. 7, 568 (2019).","journal-title":"Front. Chem."},{"key":"2732_CR34","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1021\/jm00111a032","volume":"34","author":"Y Karton","year":"1991","unstructured":"Karton, Y., Bradbury, B. J., Baumgold, J., Paek, R. & Jacobson, K. A. Functionalized congener approach to muscarinic antagonists: Analogs of pirenzepine. J. Med. Chem. 34, 2133\u20132145 (1991).","journal-title":"J. Med. Chem."},{"key":"2732_CR35","unstructured":"SciFinder. https:\/\/scifinder.cas.org."},{"key":"2732_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2042-7158.1984.tb06936.x","volume":"36","author":"J Feeney","year":"1984","unstructured":"Feeney, J. & Pascual, C. A 1H nmr study of the amide-bond conformational equilibrium in pirenzepine. J. Pharm. Pharmacol. 36, 187\u2013189 (1984).","journal-title":"J. Pharm. Pharmacol."},{"key":"2732_CR37","unstructured":"Test Solutions (TS). in U.S. Pharmacopeia (United States Pharmacopeial Convention, 2005)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02732-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:07:25Z","timestamp":1670090845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02732-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2732"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-02732-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23397"}}